T. Rowe Price Associates
NAUT icon

T. Rowe Price Associates’s Nautilus Biotechnolgy NAUT Stock Holding History

T. Rowe Price Associates’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77K Buy
+40,760
New +$108K ﹤0.01% 3173
2025
Q2 		– Sell
-16,078
Closed -$14K – 3118
2025
Q1 		$14K Hold
16,078
– – ﹤0.01% 3019
2024
Q4 		$28K Hold
16,078
– – ﹤0.01% 2981
2024
Q3 		$46K Hold
16,078
– – ﹤0.01% 2938
2024
Q2 		$38K Hold
16,078
– – ﹤0.01% 2883
2024
Q1 		$48K Buy
16,078
+4,239
+36% +$12K ﹤0.01% 2877
2023
Q4 		$36K Buy
11,839
+1,389
+13% +$3.97K ﹤0.01% 2844
2023
Q3 		$34K Buy
10,450
+438
+4% +$1.43K ﹤0.01% 2822
2023
Q2 		$39K Buy
+10,012
New +$28.8K ﹤0.01% 2827

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

T. Rowe Price Associates's NAUT Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Nautilus Biotechnolgy (NAUT) in Q2 2026: 40,760 shares worth $77K. The stake represents ﹤0.01% of the portfolio and ranks #3173 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in NAUT as recently as Q1 2025.

T. Rowe Price Associates first reported a position in NAUT in Q2 2023 and has held it in 9 quarters since. 93 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

  • T. Rowe Price Associates held 40,760 shares of Nautilus Biotechnolgy worth $77K as of Q2 2026.
  • Nautilus Biotechnolgy was a new T. Rowe Price Associates position in Q2 2026.
  • Nautilus Biotechnolgy made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3173 holding.
  • T. Rowe Price Associates first reported a position in Nautilus Biotechnolgy in Q2 2023 and has held it in 9 quarters since.
  • 93 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.